BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

A Phase I/II Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Pemetrexed - a Phase I, Open-label, Dose-escalation Study & a Phase II, 2 Arm, Randomized, Double-blind, Placebo-controlled Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00979576
• Other study ID #: 1199.28
• Status: Completed
• Phase: Phase 1
• First received: September 17, 2009
• Last updated: December 19, 2014
• Start date: October 2009
• Est. completion date: November 2014

Study information

• Verified date: December 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.

Phase I part The objective of the phase I part is to define the Maximum Tolerated Dose (MTD) of BIBF 1120 at a dose level up to twice daily 200 mg with standard dose of pemetrexed (500 mg/m2) and to determine the Recommended Dose (RD) for the phase II part.

Phase II, to investigate the efficacy and safety of BIBF 1120 in combination with pemetrexed (500 mg/m2) as compared to pemetrexed (500 mg/m2) + placebo

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: November 2014
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 74 Years

Eligibility

Inclusion criteria:

1. Male or female patients of age >=20 and <=74 years at informed consent

2. Histologically or cytologically confirmed, Non Small Cell Lung Cancer (NSCLC) of stage IIIB or IV or recurrent NSCLC

3. Relapse or failure of 1 first-line prior chemotherapy

4. Life expectancy of at least 3 months

5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

6. Patients who have sufficient baseline organ function over 4 weeks and whose laboratory data meet the following criteria at the enrolment

• Haemoglobin >=9.0 g/dL

• Absolute neutrophil count (ANC) >=1500/mm3

• Platelet count >=100 000/mm3

• Total bilirubin under the upper limit of normal

• AST/SGOT and/or ALT/GPT <=1.5 x upper limit of normal (if related to liver metastases <=2.5 x upper limit of normal also)

• Proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less

• Calculated creatinine clearance by Cockcroft Gault >=45 mL/min

• Prothrombin time-international normalized ratio (PT-INR) and/or partial thromboplastin time (PTT) greater than 50% deviation from normal limits

• arterial oxgen pressure (PaO2) >=60 torr or oxygen saturation by pulse-oximeter SpO2 >=92%

7. Patient has given written informed consent which must be consistent with ICH-GCP and local legislation.

Exclusion criteria:

1. Patients who have received treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with this trial or who have not recovered from side effects of such therapy (except for alopecia)

2. Patients who have received chemo-, hormone-, immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug or who have not recovered from side effects of such therapy (except for alopecia) .

3. Patients who have received radiotherapy within the following period Phase I part: the past 4 weeks prior to treatment with the trial drug (in case of palliative radiotherapy such as for extremities, within the past 2 weeks prior to treatment with the trial drug)

4. Previous therapy with other vascular endothelial growth factor receptor (VEGFR) inhibitors or vascular endothelial growth factor (VEGF) ligand inhibitors for treatment of NSCLC

5. Previous therapy with BIBF 1120 and/or pemetrexed for treatment of NSCLC and any contraindications for therapy with pemetrexed

6. Patients who have active brain metastases

7. Leptomeningeal disease

8. Patients with distinct or suspected pulmonary fibrosis or interstitial lung disease by the CT findings, or patients with a previous history of pulmonary fibrosis or interstitial lung disease (except irradiation-pneumonitis appearing radiation field with past radiotherapy).

9. Radiographic evidence of cavitary or necrotic tumors

10. Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels

11. History of clinically significant haemoptysis within the past 3 months

12. History of major thrombotic or clinically relevant major bleeding event in the past 6 months

13. Known inherited predisposition to bleeding or thrombosis

14. Significant cardiovascular diseases

15. Significant weight loss (>10%) within the past 6 weeks prior to treatment in the present trial

16. Current peripheral neuropathy CTCAE grade 2 or greater except due to trauma

17. Pre-existing ascites and/or clinically significant pleural effusion

18. Major injuries and/or surgery within the past 4 weeks prior to randomisation with incomplete wound healing

19. Clinically serious infections

20. Decompensated diabetes mellitus

21. Contraindication to high dose steroid therapy

22. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug

23. Patients who have active or chronic hepatitis C and/or B infection and diagnosis of human immunodeficiency virus (HIV) infection

24. Other malignancy other than basal cell skin cancer, carcinoma in situ or intra-mucosal cancer that were judged to be cured by adequate treatment and disease-free interval is more than 5 years

25. History of serious drug hypersensitivity

26. Serious illness or concomitant non-oncological disease such as neurologic-, psychiatric-, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation

27. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy

28. Patients who are sexually active and unwilling to use a medically acceptable method of contraception

29. Pregnancy or breast feeding

30. Active alcohol or drug abuse

31. Patients unable to comply with the protocol

32. Other patients judged ineligible for enrolment in the study by the investigator or subinvestigator.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• BIBF 1120 M + Pemetrexed
BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m2
• BIBF 1120 H + Pemetrexed
BIBF 1120 high dose bid+ Pemetrexed 500 mg/m2
• BIBF 1120 RD + Pemetrexed
confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m2
• BIBF 1120 L + Pemetrexed
BIBF 1120 low dose bid+ Pemetrexed 500 mg/m2
• BIBF 1120 Placebo + Pemetrexed
placebo BIBF 1120 bid + Pemetrexed 500 mg/m2

Locations

Country	Name	City	State
Japan	1199.28.003 Boehringer Ingelheim Investigational Site	Chiba,Kashiwa
Japan	1199.28.002 Boehringer Ingelheim Investigational Site	Miyakojima-ku, Osaka
Japan	1199.28.001 Boehringer Ingelheim Investigational Site	Osaka-Sayama, Osaka

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Limiting Toxicity (DLT) in Combination Therapy of BIBF 1120 and Pemetrexed During the First Course	Number of patients with dose limiting toxicity (DLT) in combination therapy of BIBF 1120 and pemetrexed during the first course	during the first course	No
Primary	Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses	Number of patients with adverse events according to Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 for all courses	Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 912 days	No
Secondary	Objective Tumor Response	Complete response (CR) or Partial response (PR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0	Pre-treatment, every 6 weeks after start of study treatment, end of treatment	No
Secondary	Disease Control	Complete response (CR) or partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0	Pre-treatment, every 6 weeks after start of study treatment, end of treatment	No
Secondary	Clinical Relevant Abnormalities in Laboratory Parameters	Clinical Relevant Abnormalities in laboratory parameters reported as adverse events	Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 912 days	No

External Links

•   Related Info